Celebrating Innovation: Georgia Bio Summit 2024 Company Showcase Winners

Celebrating Innovation: Georgia Bio Summit 2024 Company Showcase Winners

The Georgia Bio Summit 2024 was a remarkable gathering of life sciences leaders, innovators, and changemakers. This year’s Company Showcase featured 10 groundbreaking companies, all showcasing the cutting-edge innovation happening right here in Georgia and beyond. The level of competition was truly exceptional, and we are excited to announce the Top 3 Winners of the 2024 Showcase Summit:



1st Place: OrthoPreserve

OrthoPreserve impressed the judges with its innovative solutions in regenerative medicine and tissue preservation, paving the way for advancements in orthopedic care. Their work is not only transforming how we approach patient recovery but also demonstrating the impact of cutting-edge research in improving outcomes.


2nd Place: JellyCo USA

JellyCo USA stood out with its groundbreaking advancements in marine biomaterials. Their work is leading the charge in sustainable and scalable solutions for various applications, creating a meaningful impact on the future of life sciences.


3rd Place: NeurOp

NeurOp continues to push boundaries in neurological drug development, addressing unmet needs for patients with brain and nervous system disorders. Their innovation reflects a deep commitment to improving lives through science and discovery.


Honoring All Participants

While we celebrate our winners, we want to shine a spotlight on the other incredible companies that were part of this year’s showcase. These organizations exemplify the innovative spirit driving life sciences forward:

  • Atomistic Insights
  • Autofrax
  • Lena Biosciences
  • ARNAV Biotech
  • Intelligent Dots
  • Annoviant
  • OncoSpherix


Your dedication to advancing health and science inspires us all. Each of you contributes to making Georgia a hub for life sciences innovation, and we are honored to have you as part of our community.


A Bright Future for Georgia Life Sciences

This year’s Company Showcase proved that the future of life sciences in Georgia is brighter than ever. The level of talent, innovation, and collaboration on display underscores the importance of fostering a thriving ecosystem for startups and established companies alike.

As we look ahead, Georgia Bio remains committed to supporting these companies through programs, partnerships, and initiatives that drive growth and opportunity in the life sciences sector. Together, we’re not just building businesses – we’re improving lives and creating a healthier tomorrow.


Congratulations again to all participants and especially to our winners, OrthoPreserve, JellyCo USA, and NeurOp. We can’t wait to see the incredible advancements you’ll achieve in the coming years.


#GeorgiaBioSummit #LifeSciences #Innovation #Entrepreneurship #CompanyShowcase2024

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS